- $85.70m
- -$97.13m
- $0.32m
- 29
- 26
- 56
- 30
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.44 | ||
| Price to Tang. Book | 0.44 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 264.52 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -47.89% | ||
| Return on Equity | -36.5% | ||
| Operating Margin | -28723.77% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 12.52 | 5.37 | 1.98 | 33.82 | 0.32 | 5.17 | 2.14 | -46.24% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Chimerix, Inc. is a biotechnology company. The Company is focused on developing medicines that address unmet medical needs. The Company's product Imipridones is a cancer therapy that provides ONC201, which is in clinical-stage development for H3 K27M-mutant glioma as its lead indication. In addition, imipridone ONC206 is in dose-escalating clinical trials. Imipridones target specific G protein-coupled receptors (GPCRs) and mitochondrial caseinolytic protease P (ClpP), resulting in cancer cell death. The Company's product Imipridone chemical scaffold provides an opportunity to target GPCRs and ClpP with tunable specificity and modality, which enables therapeutic use for cancer and other diseases. Its ONC206 is an imipridone, Dopamine Receptor D2 (DRD2) antagonist and ClpP agonist. Its ONC212 is an imipridone, an investigational agonist of the orphan GPCR tumor suppressor GPR132, as well as ClpP. Its CMX521 is a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2.
Directors
- Martha Demski NEC (68)
- Michael Sherman PRE (55)
- Michael Andriole CFO (48)
- Allen Melemed OTH (57)
- Catherine Gilliss IND (72)
- Patrick Machado IND (57)
- Robert Meyer IND (62)
- Fred Middleton IND (71)
- Pratik Multani IND (54)
- Vicki Vakiener IND (57)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- April 7th, 2000
- Public Since
- April 11th, 2013
- No. of Shareholders
- 71
- No. of Employees
- 72
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Market- Shares in Issue
- 89,210,356
- Address
- 2505 Meridian Parkway, Suite 100, DURHAM, 27713
- Web
- https://www.chimerix.com/
- Phone
- +1 9198061074
- Auditors
- Ernst & Young LLP
Upcoming Events for CMRX
Q2 2024 Chimerix Inc Earnings Release
Similar to CMRX
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Adagene
NASDAQ Global Market
FAQ
What is the Chimerix share price?
As of Today at 19:19 UTC, shares in Chimerix are trading at $0.96. This share price information is delayed by 15 minutes.
How has the Chimerix share price performed this year?
Shares in Chimerix last closed at $0.96 and the price had moved by -23.14% over the past 365 days. In terms of relative price strength the Chimerix share price has underperformed the S&P500 Index by -37.93% over the past year.
What are the analyst and broker recommendations for Chimerix?
The overall consensus recommendation for Chimerix is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Chimerix dividend yield?
Chimerix does not currently pay a dividend.
Does Chimerix pay a dividend?
Chimerix does not currently pay a dividend.
When does Chimerix next pay dividends?
Chimerix does not currently pay a dividend.
How do I buy Chimerix shares?
To buy shares in Chimerix you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Chimerix?
As of the previous close price of $0.96, shares in Chimerix had a market capitalisation of $85.70m.
Where are Chimerix shares listed?
Here are the trading details for Chimerix:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: CMRX
What kind of share is Chimerix?
Based on an overall assessment of its quality, value and momentum Chimerix is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Chimerix share price forecast for 2024?
The analyst consensus target price for shares in Chimerix is $7.00. That is 628.64% above the last closing price of $0.96.
Analysts covering Chimerix currently have a consensus Earnings Per Share (EPS) forecast of -$0.85 for the next financial year.
What is the trend in the Chimerix share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Chimerix. Over the past six months, its share price has underperformed the S&P500 Index by -16.69%.
As of the last closing price of $0.96, shares in Chimerix were trading -7.11% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Chimerix PE Ratio?
The Chimerix PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.96.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Chimerix?
Chimerix's management team is headed by:
- Martha Demski - NEC
- Michael Sherman - PRE
- Michael Andriole - CFO
- Allen Melemed - OTH
- Catherine Gilliss - IND
- Patrick Machado - IND
- Robert Meyer - IND
- Fred Middleton - IND
- Pratik Multani - IND
- Vicki Vakiener - IND